BioNTech takes its first cancer vaccine into phase 2It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on Share XBioNTech takes its first cancer vaccine into phase 2https://pharmaphorum.com/news/biontech-takes-its-first-cancer-vaccine-bnt111-into-phase-2/
IO Biotech raises $155m to develop breakthrough cancer vaccineIO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) Share XIO Biotech raises $155m to develop breakthrough cancer vaccinehttps://pharmaphorum.com/news/io-biotech-raises-155m-to-develop-breakthrough-cancer-vaccine/
Regeneron pairs with BioNTech on melanoma immunotherapyRegeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech Share XRegeneron pairs with BioNTech on melanoma immunotherapyhttps://pharmaphorum.com/news/regeneron-pairs-with-biontech-on-melanoma-immunotherapy/
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surgeRoche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – Share XRoche’s Tecentriq claims melanoma OK, but don’t expect a sales surgehttps://pharmaphorum.com/news/roches-tecentriq-claims-melanoma-ok-but-dont-expect-a-sales-surge/
Merck builds case for six-week Keytruda dosing as FDA starts reviewMerck & Co’s checkpoint inhibitor Keytruda can be given half as often and still retain its efficacy, according Share XMerck builds case for six-week Keytruda dosing as FDA starts reviewhttps://pharmaphorum.com/news/merck-builds-case-for-six-week-keytruda-dosing-as-fda-starts-review/
BMS’ Opdivo/Yervoy combo hits a snag in adjuvant melanomaBristol-Myers Squibb’s checkpoint inhibitor combination of Opdivo and low-dose Yervoy is key to its future plans in immuno-oncology, Share XBMS’ Opdivo/Yervoy combo hits a snag in adjuvant melanomahttps://pharmaphorum.com/news/bms-opdivo-yervoy-combo-hits-a-snag-in-adjuvant-melanoma/
UK startup Ervaxx targets ‘dark matter’ of human genomeAfter two years in stealth mode, London-based biotech Ervaxx has officially launched with $17.5 million in first-round financing Share XUK startup Ervaxx targets ‘dark matter’ of human genomehttps://pharmaphorum.com/news/uk-startup-ervaxx-targets-dark-matter-of-human-genome/
As Lyrica patent expiry looms, Pfizer buys Array for $11.4bnPfizer has a made a $48 per share play for Array Biopharma, which values the cancer specialist at Share XAs Lyrica patent expiry looms, Pfizer buys Array for $11.4bnhttps://pharmaphorum.com/news/as-lyrica-patent-expiry-looms-pfizer-buys-array-for-11-4bn/
Keytruda gets okay from FDA for adjuvant melanomaThe US FDA has approved Merck & Co’s Keytruda as an adjuvant treatment for patients with melanoma who Share XKeytruda gets okay from FDA for adjuvant melanomahttps://pharmaphorum.com/news/keytruda-gets-okay-from-fda-for-adjuvant-melanoma/
